VANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the […]
Other News
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment of Dr. Eric Rose as the Company’s Chief Medical Officer (CMO). Dr. Rose has been a non-executive director of Mesoblast since 2013. In […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2022 it granted stock options to purchase an aggregate of 200,700 shares of common stock to 15 new employees, whose employment commenced in January 2022, as a material inducement to […]
SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study
Data will be available to researchers studying a wide range of disease states BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the […]
Cleerly Named to NYC Digital Health 100 by New York City Health Business Leaders
Organization recognizes the most promising and innovative health startups in New York NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized the company on […]
Paragonix Technologies LUNGguard™ Used in Record Cross-Country Donor Lung Transplant Case
Device enables donor lungs to safely travel unprecedented distance of 4,788 Miles with a total ischemic time of over 13 hours CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest […]
FDA Clears World’s First Credit-Card-Sized Personal ECG
AliveCor launches KardiaMobile Card, the only personal ECG slim enough to fit in a wallet for instant feedback on heart health anytime, anywhere MOUNTAIN VIEW, Calif., Feb. 1, 2022 /PRNewswire/ — AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaMobile Card, the slimmest, most convenient personal […]
Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM
Aficamten Reduced LVOT Gradients in Patients on Disopyramide With No Instances of Left Ventricular Ejection Fraction Below 50% Findings Support Inclusion of Patients on Disopyramide in SEQUOIA-HCM SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of […]
Englewood Health Receives Prestigious National Certification for Heart Valve Program
Bergen County’s first hospital to earn recognition from the American College of Cardiology for Transcatheter Valve ENGLEWOOD, N.J., Feb. 1, 2022 /PRNewswire/ — Englewood Health has been recognized by the American College of Cardiology (ACC) with the Transcatheter Valve Certification. This mark of distinction reflects the accomplishments of the Structural Heart and […]
LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the […]



